β-catenin antisense treatment decreases β-catenin expression and tumor growth rate in colon carcinoma xenografts

Journal of Surgical Research

Volumn 101, Issue 1, 2001, Pages 16-20

  Green, Douglas W ^a   Roh, Haeri ^a   Pippin, James A ^a   Drebin, Jeffrey A ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adenomatous polyposis coli gene (APC); Antisense; Colon cancer; catenin

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; APC PROTEIN; BETA CATENIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; COLON CARCINOMA; COLON POLYPOSIS; CONTROLLED STUDY; FEMALE; GENE THERAPY; HUMAN; HUMAN TISSUE; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR SUPPRESSOR GENE; TUMOR XENOGRAFT;

EID: 0034760407     PISSN: 00224804     EISSN: None     Source Type: Journal    
DOI: 10.1006/jsre.2001.6241     Document Type: Article

References (22)

1. Colon cancer
2. A genetic model for colorectal tumorigenesis
3. Mutations in the APC gene and their implications for protein structure and function
4. Association of the APC gene product with β-catenin
5. Association of the APC tumor suppresser protein with catenins
6. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC
7. Biology of the adenomatous polyposis coli tumor suppresser
8. The interactions of APC, E-cadherin and β-catenin in tumor development and progression
9. Suppression of β-catenin inhibits the neoplastic growth of APC-mutant colon cancer cells
10. Antisense oligonucleotides: An evolving technology for the modulation of gene expression in human disease
11. Apoptosis and APC in colorectal tumorigenesis
12. The tumor suppresser gene product APC blocks cell cycle progression from G0/G1 to S phase
13. Identification of c-MYC as a target of the APC pathway
14. Cadherin and catenin biology represent a global mechanism for epithelial cancer progression
15. Identification of c-MYC as a target of the APC pathway
16. Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells
17. The metalloproteinase matrilysin is a target of beta-catenin transactivation in intestinal tumors
18. C-raf-1 depletion and tumor responses in patients treated with the c-raf-1 antisense oligodeoxynucleotide ISIS 5132
19. Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with nora Hodgkin's lymphoma
20. Beta and gamma-catenin mutations, but not E-cadherin inactivation, underlie T-cell factor/lymphoid enhancer factor transcriptional deregulation in gastric and pancreatic cancer
21. Beta-catenin, a novel marker for breast cancer: Its roles in cyclin D1 expression and cancer progression